Physician profile
Baldev David Singh
NPI 1528088515
$235.77
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $20.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $87.90 | 2019 | |
| Daiichi Sankyo INC. | $36.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.58 | 2019 | |
| Forte Bio-Pharma LLC | $20.72 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.35 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $16.20 | 2019 | |
| Biodelivery Sciences International, INC. | $15.47 | 2019 | |
| Pfizer INC. | $13.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baldev Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.